- AbbVie has raised its full-year adjusted Earnings Per Share (EPS) forecast to a range of $10.71 to $10.91.
- For the second quarter, AbbVie reported adjusted EPS of $2.65, beating the estimate of $2.56.
- Net revenue for the second quarter was $14.46 billion, surpassing the forecasted $14.03 billion.
- Specific product revenues were reported as follows:
- Humira: $2.81 billion (estimate: $2.79 billion)
- Skyrizi: $2.73 billion (estimate: $2.61 billion)
- Rinvoq: $1.43 billion (estimate: $1.34 billion)
- Imbruvica: $833 million (estimate: $784.3 million)
- Venclexta: $637 million (estimate: $603.8 million)
- Botox – Cosmetic: $729 million (estimate: $741.4 million)
- Juvederm: $343 million (estimate: $378.3 million)
- Botox – Therapeutic: $814 million (estimate: $796.6 million)
- Vraylar: $774 million (estimate: $813.2 million)
- Ubrelvy: $231 million (estimate: $233.9 million)
- The adjusted gross margin for the quarter was 85.2%, slightly exceeding the estimate of 84.7%.
- The updated guidance includes an unfavorable impact of $0.60 per share due to acquired IPR&D and milestones expense incurred year-to-date through the second quarter of 2024.
- The adjusted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the second quarter, as these cannot be reliably forecasted.
Abbvie Inc on Smartkarma
On Smartkarma, analysts from Baptista Research have been providing insightful coverage of AbbVie Inc. One report titled “AbbVie Inc.: Acquisition of Landos Biopharma to Enhance Autoimmune Disease Treatments & Other Major Developments” highlights the company’s strong performance in the first quarter of 2024. AbbVie exceeded expectations with adjusted earnings per share of $2.31 and total net revenues of $12.3 billion, showcasing the strength of its diversified pharmaceutical portfolio with long-term growth prospects.
Another report by Baptista Research, “AbbVie Inc: Produodopa’s Green Light In Scotland & 6 Other Major Developments – Key Drivers,” details AbbVie Inc.’s impressive performance in the fourth quarter of 2023. The company’s growth platform, beyond its flagship product Humira, reported significant full-year sales growth exceeding 8%. These reports reflect a bullish sentiment and provide valuable insights for investors following AbbVie Inc.’s developments.
A look at Abbvie Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbvie Inc, a pharmaceutical company that focuses on research and development of drugs in various specialty therapeutic areas, has a mixed outlook according to Smartkarma Smart Scores. While Abbvie scores well in terms of dividend and growth potential, its value and resilience scores are relatively lower. This indicates that investors may find Abbvie attractive for its dividend payments and growth prospects, but should consider the company’s valuation and resilience to market fluctuations when making investment decisions.
AbbVie Inc. researches and develops pharmaceutical products for a range of medical conditions including immunology, chronic kidney disease, Hepatitis C, women’s health, oncology, and neuroscience. Additionally, AbbVie offers treatments for diseases like Multiple Sclerosis, Parkinson’s, and Alzheimer’s disease. With a diverse portfolio of pharmaceutical products, Abbvie’s overall long-term outlook may be influenced by factors such as its ability to sustain growth, manage market challenges, and continue providing value to shareholders.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
